GlassScriptPhysician profile
Albert Elias Smith
NPI 1891777298
$9,914.19
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,259 · 2020: $2,338 · 2021: $2,102 · 2022: $1,576 · 2023: $1,569 · 2024: $69.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,753.34 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,464.70 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $886.83 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $784.45 | 2019-2022 | |
| Amarin Pharma, INC. | $550.84 | 2019-2021 | |
| Abbvie INC. | $496.57 | 2021-2023 | Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $462.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.93 | 2019-2021 | |
| Pfizer INC. | $334.48 | 2019-2024 | |
| Lilly USA, LLC | $309.89 | 2019-2023 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $275.81 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $268.78 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $218.67 | 2019-2022 | |
| Eisai INC. | $197.71 | 2020-2021 | |
| Esperion Therapeutics, INC. | $188.00 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.